Literature DB >> 6690196

The stability of gastric acid secretion during prolonged pentagastrin stimulation in man.

B Petersen, J Christiansen, P Kirkegaard, P S Olsen.   

Abstract

Prolonged stimulation with pentagastrin in doses of 100 and 500 ng h-1 kg-1 was performed in nine healthy subjects. A plateau in gastric secretion was reached after 90 min with 100 ng h-1 kg-1 and 500 ng h-1 kg-1 resulted in a secretory plateau after 60 min. When the plateau was reached the acid secretion rate was constant for the rest of the study, that is 4 h after beginning the pentagastrin infusion. Medians and interquartile ranges of acid output were 4.9 (3.7-5.2) and 8.1 (5.8-9.5) mmol of H+/30 min. We conclude that no 'fade' of gastric acid secretion occurs during 4 h of submaximal pentagastrin stimulation in normal subjects, and that the time required for reaching a secretory plateau is dependent on the dose of pentagastrin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690196     DOI: 10.1042/cs0660099

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

1.  GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans.

Authors:  B T Schjoldager; P E Mortensen; J Christiansen; C Orskov; J J Holst
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

2.  Effect of low-dose exogenous secretin on pentagastrin- and meal-stimulated gastric acid secretion in humans.

Authors:  J Christiansen; B Hansen; L Hilsted; O B Schaffalitzky de Muckadell
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

3.  L-643.441: an H2-receptor antagonist with potent and long-lasting effects in man.

Authors:  D A Henry; K W Somerville; G K Kitchingman; I B Holmes; J A Tobert; M J Langman
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

4.  Inhibition of pentagastrin-stimulated acid secretion after subcutaneous administration of a new somatostatin analogue.

Authors:  I Whitehouse; C Beglinger; G Rüttimann; K Gyr
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

5.  A formulated poly (I:C)/CCL21 as an effective mucosal adjuvant for gamma-irradiated influenza vaccine.

Authors:  Ailar Sabbaghi; Masoud Malek; Sara Abdolahi; Seyed Mohammad Miri; Leila Alizadeh; Mehdi Samadi; Seyed Reza Mohebbi; Amir Ghaemi
Journal:  Virol J       Date:  2021-10-09       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.